Form 8-K - Current report:
SEC Accession No. 0001558370-22-017872
Filing Date
2022-11-14
Accepted
2022-11-14 17:23:59
Documents
16
Period of Report
2022-11-14
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imgn-20221114x8k.htm   iXBRL 8-K 47234
2 EX-99.1 imgn-20221114xex99d1.htm EX-99.1 46678
3 GRAPHIC imgn-20221114xex99d1001.jpg GRAPHIC 7018
  Complete submission text file 0001558370-22-017872.txt   326420

Data Files

Seq Description Document Type Size
4 EX-101.SCH imgn-20221114.xsd EX-101.SCH 4058
5 EX-101.DEF imgn-20221114_def.xml EX-101.DEF 3240
6 EX-101.LAB imgn-20221114_lab.xml EX-101.LAB 636
7 EX-101.PRE imgn-20221114_pre.xml EX-101.PRE 10106
10 EXTRACTED XBRL INSTANCE DOCUMENT imgn-20221114x8k_htm.xml XML 4688
Mailing Address 830 WINTER ST WALTHAM MA 02451
Business Address 830 WINTER ST WALTHAM MA 02451 (781)895-0600
ImmunoGen, Inc. (Filer) CIK: 0000855654 (see all company filings)

EIN.: 042726691 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-17999 | Film No.: 221387921
SIC: 2834 Pharmaceutical Preparations